New progress in the first-line treatment of advanced hepatocellular carcinoma
10.3760/cma.j.cn501113-20231114-00193
- VernacularTitle:晚期肝细胞癌一线治疗新进展
- Author:
Chuanhui ZHANG
1
;
Dongyue YAO
;
Siqi LIU
;
Lanlan YANG
;
Zhenjing JIN
Author Information
1. 吉林大学第二医院肝胆胰内科，长春 130041
- Keywords:
Hepatocellular carcinoma;
Targeted therapy;
Immunotherapy;
Combination therapy
- From:
Chinese Journal of Hepatology
2024;32(2):173-179
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods. Combination therapy has significant synergistic effects and thus has already become a future treatment trend for hepatocellular carcinoma. An immunotherapy-based combination therapy plan will run through the whole process of systemic therapy, which is expected to bring better survival benefits to patients with hepatocellular carcinoma. This article reviews the latest research progress in aspects of the first-line treatment of advanced hepatocellular carcinoma.
